Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease

Blood

Volumn 118, Issue 22, 2011, Pages 5767-5773

  Zimran, Ari ^a   Brill Almon, Einat ^b   Chertkoff, Raul ^b   Petakov, Milan ^c   Blanco Favela, Francisco ^d   Muñoz, Eduardo Terreros ^d   Solorio Meza, Sergio E ^e   Amato, Dominick ^f   Duran, Gloria ^g   Giona, Fiorina ^h   Heitner, Rene ⁱ   Rosenbaum, Hanna ^j   Giraldo, Pilar ^k   Mehta, Atul ^l   Park, Glen ^m   Phillips, Mici ^a   Elstein, Deborah ^a   Altarescu, Gheona ^a   Szleifer, Mali ^b   Hashmueli, Sharon ^b   Aviezer, David ^b   more..

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b Protalix Biotherapeutics   (Israel)

^c UNIVERSITY OF BELGRADE   (Serbia)

^d INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^e Gto   (Mexico)

^f MOUNT SINAI HOSPITAL   (Canada)

^g PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^j RAMBAM MEDICAL CENTER   (Israel)

^k Hospital Universitario   (Spain)

^l ROYAL FREE HOSPITAL   (United Kingdom)

^m Target Health Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHITOTRIOSIDASE; HEMOGLOBIN; IMMUNOGLOBULIN G ANTIBODY; TALIGLUCERASE ALFA;

ABDOMINAL PAIN; ADULT; AGED; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BONE RADIOGRAPHY; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; ENZYME REPLACEMENT; FEMALE; GAUCHER DISEASE; GLUCOSURIA; HEMOGLOBIN DETERMINATION; HOT FLUSH; HUMAN; INSTITUTIONAL REVIEW; LIVER WEIGHT; MALE; MAXIMUM PLASMA CONCENTRATION; MUSCLE SPASM; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; PLANT CELL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN IRRITATION; SPLEEN SIZE; SPLENOMEGALY; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 82155184565     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-07-366955     Document Type: Article

References (26)

1. Barton NW, Brady RO, Dambrosia JM, et al. Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med. 1991; 324(21):1464-1470.
2. Grabowski GA, Barton NW, Pastores G, et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med. 1995;122(1):33-39.
3. Zimran A, Elstein D, Levy-Lahad E, et al. Replacement therapy with imiglucerase for type 1 Gaucher's disease. Lancet. 1995;345(8963): 1479-1480.
4. Starzyk K, Richards S, Yee J, Smith SE, Kingma W. The long-term international safety experience of imiglucerase therapy for Gaucher disease. Mol Genet Metab. 2007;90(2):157-163. (Pubitemid 46108612)
5. Weinreb N, Taylor J, Cox T, Yee J, vom Dahl S. A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase. Am J Hematol. 2008; 83(12):890-895.
6. Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol. 2004;41(4 suppl 5):4-14. (Pubitemid 39311677)
7. Connock M, Burls A, Frew E, et al. The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review. Health Technol Assess. 2006; 10:iii-iv, ix-136.
8. Sidransky E, Pastores G, Mori M. Dosing enzyme replacement therapy for Gaucher disease: older, but are we wiser? Genet Med. 2009;11(2):90-91.
9. Halpern SD, Karlawish JH, Berlin JA. The continuing unethical conduct of underpowered clinical trials. J Am Med Assoc. 2002;288(3):358-362. (Pubitemid 34761615)
10. Hollak CE, vom Dahl S, Aerts JM, et al. Force Majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. Blood Cells Mol Dis. 2010;44(1):41-47.
11. Cox TM. Recommendations for treating patients with Gaucher disease with emerging enzyme products. Blood Cells Mol Dis. 2010;44(2):84-85.
12. Steinbrook R. Drug shortages and public health. N Engl J Med. 2009;361(16):1525-1527.
13. Aviezer D, Brill-Almon E, Shaaltiel Y, et al. A plant-derived recombinant human glucocerebrosidase enzyme-a preclinical and phase I investigation. PLoS One. 2009;4(3):e4792.
14. Shaaltiel Y, Bartfeld D, Hashmueli S, et al. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system. Plant Biotechnol J. 2007;5(5):579-590. (Pubitemid 47196361)
15. Kaiser J. Is the drought over for pharming? Science. 2008;320(5875):473- 475.
16. Fairley C, Zimran A, Phillips M, et al. Phenotypic heterogeneity of N370S homozygotes with type I Gaucher disease: an analysis of 798 patients from the ICGG Gaucher Registry. J Inherit Metab Dis. 2008;31(6):738-744.
17. Bracoud L, Ahmad H, Brill Almon E, Chertkoff R. Measurement of spleen and liver volumes using MRI in a multi-center trial on treatment-naïve patients with Gaucher disease before and during enzyme-replacement therapy. Blood Cells Mol Dis. 2011;46(1):47-52.
18. Maas M, Hollak CE, Akkerman EM, Aerts JM, Stoker J, Den Heeten GJ. Quantification of skeletal involvement in adults with type I Gaucher's disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter. Am J Roentgenol. 2002;179(4):961-965.
19. Zimran A, Altarescu G, Phillips M, et al. Phase 1/2 and extension study of velaglucerase alfa (geneactivated human glucocerebrosidase) replacement therapy in adults with type 1 Gaucher disease: 48-month experience. Blood. 2010;115(23): 4651-4656.
20. Zimran A, Loveday K, Fratazzi C, Elstein D. A pharmacokinetic analyis of a novel enzyme replacement therapy with gene-activated(R) human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher disease. Blood Cells Mol Dis. 2007;39(1):115-118. (Pubitemid 46754922)
21. Cox TM, Aerts JM, Andria G, et al. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis. 2003;26(6):513-526. (Pubitemid 37321530)
22. Zimran A, Elstein D, Kannai R, et al. Low-dose enzyme replacement therapy for Gaucher's disease: effects of age, sex, genotype, and clinical features on response to treatment. Am J Med. 1994;97(1):3-13. (Pubitemid 24223628)
23. de Fost M, Hollak CE, Groener JE, et al. Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis. Blood. 2006;108(3):830- 835.
24. Zimran A, Elstein D. Lipid storage diseases. In: Lichtman MA, Kipps T, Seligsohn U, Kaushansky K, Prchal JT, eds.Williams Hematology. 8th ed. New York, NY: McGraw-Hill; 2010:1065-1071.
25. Grabowski GA, Kacena K, Cole JA, et al. Doseresponse relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1. Genet Med. 2009; 11(2):92-100.
26. Stein P, Malhotra A, Haims A, Pastores GM, Mistry PK. Focal splenic lesions in type I Gaucher disease are associated with poor platelet and splenic response to macrophage-targeted enzyme replacement therapy. J Inherit Metab Dis. 2010;33(6):769-774.